{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:22:37Z","timestamp":1792110157445,"version":"4.4.0"},"reference-count":85,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T00:00:00Z","timestamp":1725753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hypertriglyceridemia therapy is essential for preventing cardiovascular diseases. Fibrates belong to an important class of lipid-lowering drugs useful for the management of dyslipidaemia. By acting on the peroxisome proliferator-activated receptor (PPAR)-\u03b1, these drugs lower serum triglyceride levels and raise high-density lipoprotein cholesterol. Fibrate monotherapy is associated with a risk of myopathy and this risk is enhanced when these agents are administered together with statins. However, whereas gemfibrozil can increase plasma concentrations of statins, fenofibrate has less influence on the pharmacokinetics of statins. Pemafibrate is a new PPAR-\u03b1-selective drug considered for therapy, and clinical trials are ongoing. Apart from this class of drugs, new therapies have emerged with different mechanisms of action to reduce triglycerides and the risk of cardiovascular diseases.<\/jats:p>","DOI":"10.3390\/ijms25179727","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T05:59:08Z","timestamp":1725861548000},"page":"9727","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Hypertriglyceridemia Therapy: Past, Present and Future Perspectives"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6357-316X","authenticated-orcid":false,"given":"Ileana","family":"Canfora","sequence":"first","affiliation":[{"name":"Section of Pharmacology, Department of Pharmacy and Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70121 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabata","family":"Pierno","sequence":"additional","affiliation":[{"name":"Section of Pharmacology, Department of Pharmacy and Drug Sciences, University of Bari \u201cAldo Moro\u201d, 70121 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","article-title":"European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"33","author":"Perk","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"i56","DOI":"10.1093\/eurheartjsupp\/suae007","article-title":"Lipid-lowering approaches to manage statin-intolerant patients","volume":"26","author":"Ruscica","year":"2024","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1177\/08971900211053489","article-title":"Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline","volume":"36","author":"Xu","year":"2023","journal-title":"J. Pharm. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.2174\/1381612811319170020","article-title":"The role of fibrate treatment in dyslipidemia: An overview","volume":"19","author":"Katsiki","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/01.CIR.39.5.675","article-title":"Long-term effects of clofibrate (Atromid-S) on serum lipids in man","volume":"39","author":"Hunninghake","year":"1969","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2165\/00003495-197306010-00003","article-title":"Lipid lowering drugs and hyperlipidaemia","volume":"6","author":"Levy","year":"1973","journal-title":"Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(01)06489-3","article-title":"Learning from the cerivastatin experience","volume":"358","author":"Farmer","year":"2001","journal-title":"Lancet"},{"key":"ref_10","first-page":"205","article-title":"Withdrawal of cerivastatin from the world market","volume":"2","author":"Furberg","year":"2001","journal-title":"Curr. Control. Trials Cardiovasc. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1476-5381.2008.00079.x","article-title":"Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression","volume":"156","author":"Pierno","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.bcp.2011.01.022","article-title":"Statin or fibrate chronic treatment modifies the proteomic profile of rat skeletal muscle","volume":"81","author":"Camerino","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1476-5381.2008.00083.x","article-title":"Statins and fibrate target ClC-1-from side effects to CLC pharmacology","volume":"156","author":"Zdebik","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Pierno, S., and Musumeci, O. (2023). Pharmacotherapy of the Lipid-Lowering Drugs: Update on Efficacy and Risk. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24020996"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.mrfmmm.2003.12.019","article-title":"Profiling of hepatic gene expression in rats treated with fibric acid analogs","volume":"549","author":"Cornwell","year":"2004","journal-title":"Mutat. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.bbrc.2005.02.070","article-title":"Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle","volume":"329","author":"Sirvent","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1124\/jpet.106.118331","article-title":"Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum\/mitochondria Ca2+-release system","volume":"321","author":"Liantonio","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.bjp.0706917","article-title":"Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: A biochemical, histological and electrophysiological study","volume":"149","author":"Pierno","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Camerino, G.M., Tarantino, N., Canfora, I., De Bellis, M., Musumeci, O., and Pierno, S. (2021). Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22042070"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00726-011-1099-4","article-title":"Potential benefits of taurine in the prevention of skeletal muscle impairment induced by disuse in the hindlimb-unloaded rat","volume":"43","author":"Pierno","year":"2012","journal-title":"Amino Acids"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0014-5793(99)00202-1","article-title":"Aging-associated down-regulation of ClC-1 expression in skeletal muscle: Phenotypic-independent relation to the decrease of chloride conductance","volume":"449","author":"Pierno","year":"1999","journal-title":"FEBS Lett."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Camerino, G.M., Fonzino, A., Conte, E., De Bellis, M., Mele, A., Liantonio, A., Tricarico, D., Tarantino, N., Dobrowolny, G., and Musar\u00f2, A. (2019). Elucidating the Contribution of Skeletal Muscle Ion Channels to Amyotrophic Lateral Sclerosis in search of new therapeutic options. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-39676-3"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"C333","DOI":"10.1152\/ajpcell.1997.272.1.C333","article-title":"Electrical properties of diaphragm and EDL muscles during the life of dystrophic mice","volume":"272","author":"Pierno","year":"1997","journal-title":"Am. J. Physiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1124\/mol.63.3.659","article-title":"Different ability of clenbuterol and salbutamol to block sodium channels predicts their therapeutic use in muscle excitability disorders","volume":"63","author":"Desaphy","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Camerino, G.M., Pierno, S., Liantonio, A., De Bellis, M., Cannone, M., Sblendorio, V., Conte, E., Mele, A., Tricarico, D., and Tavella, S. (2013). Effects of pleiotrophin overexpression on mouse skeletal muscles in normal loading and in actual and simulated microgravity. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0072028"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Camerino, G.M., Desaphy, J.F., De Bellis, M., Capogrosso, R.F., Cozzoli, A., Dinardo, M.M., Caloiero, R., Musaraj, K., Fonzino, A., and Conte, E. (2015). Effects of Nandrolone in the Counteraction of Skeletal Muscle Atrophy in a Mouse Model of Muscle Disuse: Molecular Biology and Functional Evaluation. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129686"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"113287","DOI":"10.1016\/j.expneurol.2020.113287","article-title":"Safinamide\u2019s potential in treating nondystrophic myotonias: Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo","volume":"328","author":"Desaphy","year":"2020","journal-title":"Exp. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Camerino, G.M., Musumeci, O., Conte, E., Musaraj, K., Fonzino, A., Barca, E., Marino, M., Rodolico, C., Tricarico, D., and Camerino, C. (2017). Risk of Myopathy in Patients in Therapy with Statins: Identification of Biological Markers in a Pilot Study. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00500"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1016\/j.clinph.2005.07.016","article-title":"Pain and calf hypertrophy associated with spontaneous repetitive discharges treated with botulinum toxin","volume":"116","author":"Costa","year":"2005","journal-title":"Clin. Neurophysiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00221-007-0985-1","article-title":"Experimental muscle pain decreases the frequency threshold of electrically elicited muscle cramps","volume":"182","author":"Serrao","year":"2007","journal-title":"Exp. Brain Res."},{"key":"ref_31","first-page":"45","article-title":"Carboxylic acids and chloride conductance in skeletal muscle: Influence on the pharmacological activity induced by the chain substituents and the distance between the phenolic group and the carboxylic function in 4-chloro-phenoxy alkanoic acids","volume":"48","author":"Loiodice","year":"1993","journal-title":"Farmaco"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6382","DOI":"10.1021\/jm900941b","article-title":"New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha\/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function","volume":"52","author":"Fracchiolla","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC Scientific Document Group. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_34","unstructured":"Feingold, K.R., Anawalt, B., Blackman, M.R., Boyce, A., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., Dungan, K., and Hofland, J. (2024). Triglyceride Lowering Drugs. Endotext [Internet], MDText.com, Inc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/s41467-024-46239-2","article-title":"Structure-guided engineering of biased-agonism in the human niacin receptor via single amino acid substitution","volume":"15","author":"Yadav","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Packard, C.J., Boren, J., and Taskinen, M.R. (2020). Causes and consequences of hypertriglyceridemia. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00252"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1373\/clinchem.2018.294926","article-title":"Low-grade inflammation in the association between mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis: A study of more than 115000 individuals from the general population","volume":"65","author":"Hansen","year":"2019","journal-title":"Clin. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12640-012-9338-3","article-title":"Gemfibrozil pretreatment affecting antioxidant defense system and inflammatory, but not Nrf-2 signaling pathways resulted in female neuroprotection and male neurotoxicity in the rat models of global cerebral ischemia-reperfusion","volume":"23","author":"Mohagheghi","year":"2013","journal-title":"Neurotox. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1517\/14740338.2015.1056778","article-title":"Safety considerations with fenofibrate\/simvastatin combination","volume":"14","author":"Filippatos","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/14656566.2023.2206015","article-title":"Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors","volume":"24","author":"Spagnuolo","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/CRD.0000000000000468","article-title":"Drug Therapy for Hypertriglyceridemia and Familial Chylomicronemia Syndrome: Focus on Volnesorsen","volume":"31","author":"Gesner","year":"2023","journal-title":"Cardiol. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2","DOI":"10.12997\/jla.2024.13.1.2","article-title":"Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors","volume":"13","author":"Tomlinson","year":"2024","journal-title":"J. Lipid Atheroscler."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11883-021-00918-3","article-title":"Lipid Lowering Drugs: Present Status and Future Developments","volume":"23","author":"Ruscica","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40265-019-01168-z","article-title":"Volanesorsen: First Global Approval","volume":"79","author":"Paik","year":"2019","journal-title":"Drugs"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Sosnowska, B., Adach, W., Surma, S., Rosenson, R.S., and Banach, M. (2022). Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010168"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1093\/eurheartj\/ehae321","article-title":"ANGPTL3 as a therapeutic target for treating homozygous familial hypercholesterolaemia: A shot in the arm for evinacumab","volume":"45","author":"Watts","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1089\/hum.2023.075","article-title":"Preclinical Development and Characterization of Novel Adeno-Associated Viral Vectors for the Treatment of Lipoprotein Lipase Deficiency","volume":"34","author":"Mehta","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14656566.2019.1691523","article-title":"Recent developments in pharmacotherapy for hypertriglyceridemia: What\u2019s the current state of the art?","volume":"21","author":"Florentin","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/MOL.0000000000000710","article-title":"Hypertriglyceridemia: New approaches in management and treatment","volume":"31","author":"Wolska","year":"2020","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3945\/an.111.000893","article-title":"Omega-3 fatty acids EPA and DHA: Health benefits throughout life","volume":"3","author":"Swanson","year":"2012","journal-title":"Adv. Nutr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"J49","DOI":"10.1093\/eurheartj\/suaa118","article-title":"The journey of omega-3 fatty acids in cardiovascular medicine","volume":"22","author":"Ferrari","year":"2020","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Santos-Baez, L.S., and Ginsberg, H.N. (2020). Hypertriglyceridemia-Causes, Significance, and Approaches to Therapy. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00616"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"ref_54","first-page":"CD003177","article-title":"Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease","volume":"3","author":"Abdelhamid","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/07853890.2018.1511919","article-title":"Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: A systematic review and meta-analysis of randomized controlled trials","volume":"50","author":"Sahebkar","year":"2018","journal-title":"Ann. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01.mol.0000236363.63840.16","article-title":"Why do omega-3 fatty acids lower serum triglycerides?","volume":"17","author":"Harris","year":"2006","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s11883-023-01175-2","article-title":"How to Handle Elevated Triglycerides: Life after PROMINENT","volume":"25","author":"Pirillo","year":"2023","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.phrs.2018.10.007","article-title":"The effect of artichoke on lipid profile: A review of possible mechanisms of action","volume":"137","author":"Santos","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11883-021-00955-y","article-title":"Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?","volume":"23","author":"Cicero","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.fitote.2016.02.001","article-title":"Research progress on berberine with a special focus on its oral bioavailability","volume":"109","author":"Liu","year":"2016","journal-title":"Fitoterapia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"E812","DOI":"10.1152\/ajpendo.90710.2008","article-title":"Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity","volume":"296","author":"Kim","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1440-1681.2012.05670.x","article-title":"Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention","volume":"39","author":"Meng","year":"2012","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.phymed.2015.12.005","article-title":"The effect of bergamot on dyslipidemia","volume":"23","author":"Giglio","year":"2016","journal-title":"Phytomedicine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijcard.2013.08.125","article-title":"Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia","volume":"170","author":"Gliozzi","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/ptr.6402","article-title":"Three-arm, placebo-controlled, randomized clinical trial evaluating the metabolic effect of a combined nutraceutical containing a bergamot standardized flavonoid extract in dyslipidemic overweight subjects","volume":"33","author":"Cicero","year":"2019","journal-title":"Phytother. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","article-title":"Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia","volume":"16","author":"Fruchart","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1016\/j.bmcl.2007.05.066","article-title":"Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists","volume":"17","author":"Yamazaki","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"754","DOI":"10.5551\/jat.28720","article-title":"Transcriptome analysis of K-877 (a novel selective PPARalpha modulator (SPPARMalpha))-regulated genes in primary human hepatocytes and the mouse liver","volume":"22","author":"Tanaka","year":"2015","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e020834","DOI":"10.1161\/JAHA.121.020834","article-title":"Highly Selective PPAR\u03b1 (Peroxisome Proliferator-Activated Receptor \u03b1) Agonist Pemafibrate Inhibits Stent Inflammation and Restenosis Assessed by Multimodality Molecular-Microstructural Imaging","volume":"10","author":"Iwata","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"142","DOI":"10.5551\/jat.39693","article-title":"A Novel Selective PPAR\u03b1 Modulator (SPPARM\u03b1), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice","volume":"25","author":"Sairyo","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_71","first-page":"286","article-title":"Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease","volume":"39","author":"Miller","year":"2024","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s11883-023-01140-z","article-title":"Updates in Drug Treatment of Severe Hypertriglyceridemia","volume":"25","author":"Schwarz","year":"2023","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen Study Investigators. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1093\/cvr\/cvad177","article-title":"Exploring apolipoprotein C-III: Pathophysiological and pharmacological relevance","volume":"119","author":"Packard","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Ballantyne, C.M., Vasas, S., Azizad, M., Clifton, P., Rosenson, R.S., Chang, T., Melquist, S., Zhou, R., Mushin, M., and Leeper, N.J. (2024). Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2404143"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Rosenson, R.S., Gaudet, D., Hegele, R.A., Ballantyne, C.M., Nicholls, S.J., Lucas, K.J., San Martin, J., Zhou, R., Muhsin, M., and Chang, T. (2024). Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2404147"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/cpt.3278","article-title":"Efficacy and Safety of Fibroblast Growth Factor-21 Analogs for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis","volume":"116","author":"Jeong","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/apt.17709","article-title":"Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis","volume":"58","author":"Alkhouri","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","article-title":"ENTRIGUE Principal Investigators. The FGF21 analog pegozafermin in severe hypertriglyceridemia: A randomized phase 2 trial","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nat. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1093\/eurheartj\/ehab841","article-title":"The dawn of a new era of targeted lipid-lowering therapies","volume":"43","author":"Libby","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1161\/ATVBAHA.116.307227","article-title":"CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report","volume":"36","author":"Wang","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9727\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:51:36Z","timestamp":1760111496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/17\/9727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,8]]},"references-count":85,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["ijms25179727"],"URL":"https:\/\/doi.org\/10.3390\/ijms25179727","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,8]]}}}